MedWatch

A part of Watch Media

New trial of Genmab substance is symptomatic of Deborah Dunsire's Lundbeck

The study involving the Lu AF82422 antibody illustrates several of Lundbeck's recent tendencies, including attempts to ensure a higher study success rate and more substances in the company pipeline. This goes for both the approach to development and the variety of substances.

Since Deborah Dunsire joined Lunbeck three years ago, she has been hard at work getting the success rate of the company's research and development efforts back on track. | Photo: Gregers Tycho/ERH
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

The newly announced phase II trial with the substance Lu AF82422, which is part of a collaboration between Genmab and Lundbeck, is in many ways an example of the new research strategy that Lundbeck has created under the leadership of CEO Deborah Dunsire and Head of Research and Development Johan Luthman.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Foto: Thomas Borberg/Politiken/Ritzau Scanpix

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

  1. Ambu, Coloplast and GN helped by relaxation of China's covid policy
  2. Sonova completes Hysound Group acquisition, strengthens presence in China
  3. Top news from MedWatch this week
  4. Extra data boosts Lundbeck's agitation case
  5. Acquisitions to help Coloplast attain growth goal
  6. Coloplast conducts catheter study to highlight single-use benefits
  7. FDA confirms rejection of Y-mabs' cancer drug
  8. Novo reaches share milestone, analyst credits Wegovy
  9. FDA approves Ferring microbiotica-based treatment
  10. Analyst spies alternative buyers in the wings as Cochlear's potential Oticon acquisition raises eyebrows
  11. Analyst proposes four solutions as GN battles with ghosts of debts past
  12. Former US head of Leo Pharma gets board seat at Kempharm
  13. Novo Nordisk to test best-selling substance in stroke indication
  14. ALK CFO to step down
  15. Potential Demant divestment raises competition concerns

See all

Job

See all jobs

See all jobs